Hims & Hers built much of its weight-loss business on compounded GLP-1s during the FDA's semaglutide and tirzepatide shortages. Revenue scaled hard through 2024 and early 2025, then ran into the post-shortage rules.
What's happened since: the Outsourcing Facilities Association litigation, the April 30, 2026 FDA proposal to exclude branded GLP-1s from the 503B bulks list, the University of Colorado secret-shopper study showing telehealth peptide programs that kept selling compounded GLP-1s after the shortage cleared, and Hims & Hers' own pivot toward additive formulations and broader peptide therapy programs (sermorelin, peptide stacking). The May 11 Q1 2026 print formalized the strategic pivot: revenue $608.1M (+4% YoY) below the $616.9M consensus, 2.6M subscribers (+9%), and a $92.1M net loss as gross margin compressed from 73% to 65% on the wind-down of compounded semaglutide and the start of branded Novo Nordisk Wegovy/Ozempic supply (live since March 26 — Q1 books closed March 31, so meaningful contribution comes in Q2). Full-year 2026 guidance was raised to $2.8-3.0B revenue and $275-350M Adjusted EBITDA. Analyst price targets diverged sharply after the June 29-30 FDA career-staff PCAC briefing documents concluded all seven peptides have insufficient evidence for 503A eligibility: Truist held at $23 on peptide-optionality risk while Canaccord raised to $40 on the branded-drug pivot, with BofA at $36 and Barclays at $39 (Novo Nordisk partnership).
Stories here cover the compounding strategy, regulatory exposure, and the quarterly numbers. See #hims-and-hers for the alternate spelling and #telehealth for the broader channel.
Analyst dispersion around Hims & Hers Health (NYSE: HIMS) widened this week following the FDA career-staff briefing documents released June 29-30 concluding all seven PCAC peptides have insufficient evidence for 503A bulks-list inclusion. The four fresh price targets span nearly two-to-one: Truist Securities reiterated a Hold rating with a $23 price target, citing near-term-performance strength tempered by uncertainty around peptide-compounding regulation. BofA Securities raised its price target to $36 from $25 while maintaining Neutral, noting the FDA update is negative for the company's peptide-optionality narrative but not the core weight-loss business. Barclays' Glen Santangelo raised to $39 from $29 while maintaining Overweight, crediting improvements from the renewed Novo Nordisk partnership. Canaccord's Maria Ripps raised to $40 from $32 while maintaining Buy, citing the company's transition from compounded to branded weight-loss drugs. The 74% spread from lowest to highest target reflects analyst disagreement about how much of the Hims growth story now runs through peptide optionality versus branded-GLP-1 rails.
Analyst coverage of Hims & Hers (NYSE: HIMS) ahead of the July 23-24 PCAC meeting consolidated through the weekend with two distinct framings. Leerink Partners' Michael Cherny called the PCAC vote a 'modest binary event,' acknowledging that an affirmative outcome on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, or Epitalon would open real upside starting FY2027 and beyond (peptides as a large new product category for the company's owned California compounding facility), while flagging the procedural caveat that PCAC votes have a mixed record and the FDA does not always follow committee recommendations. Canaccord Genuity reiterated a 'Buy' rating on HIMS with a $32 price target framing peptides as part of the company's long-term preventive-health, longevity, and wellness portfolio expansion. The two analyst views sit alongside Barclays' June 17 PT raise to $39 (Overweight, weight-loss-momentum thesis). HIMS stock entered Monday June 29 up roughly 29.79% in June despite a 1.62% intraday decline, with the convergence of analyst price targets and the binary July 23-24 PCAC catalyst positioning the company as one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.
Hims & Hers Health announced May 18 the pricing of an upsized $350M aggregate principal amount of 0.00% convertible senior notes due 2032, with settlement May 21. Initial conversion rate is 33.8590 shares of Class A common stock per $1,000 principal — a conversion price of approximately $29.53 per share, representing a 32.5% premium over the $22.29 close on May 18. The capped call cap price was set at approximately $50.15 per share (125% premium). Initial purchasers granted an option to buy up to an additional $52.5M in notes within 13 days. Proceeds support international expansion strategy and the proposed acquisition of Eucalyptus (Australian-based digital health platform with peptide and weight-management presence in Australia, UK, and Germany) expected to close mid-2026. The convertible structure preserves cash for the international rollout while the Novo Nordisk branded distribution partnership scales US Wegovy supply.
Hims & Hers disclosed in post-Q1 commentary picked up by Stocktwits and Yahoo Finance that the company has fulfilled approximately 125,000 Wegovy shipments since the Novo Nordisk branded-distribution partnership activated on March 26, 2026 — roughly 21,000 per week in operational terms. The volume signals materially stronger Wegovy uptake through the Hims platform than the Q1 print's $608M revenue figure suggested, with most of the contribution landing in Q2 books. Subscriber count held at 2.6M (+9% YoY), monthly average revenue per subscriber dropped to $80 from $85 on the product-mix shift, and full-year guidance was raised to $2.8-3.0B revenue. Deutsche Bank's George Hill trimmed his target to $25 from $28 (Hold). The 'Netflix of healthcare' framing from major investor Cathie Wood persists despite the post-print drop; HIMS shares partially recovered to $29.14 in early-week trading.
Hims & Hers shares fell ~13% after the May 11 Q1 print as $608.1M revenue missed the $616.9M consensus and gross margin compressed from 73% to 65% on the compounded-semaglutide wind-down. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed); Canaccord raised to $32 from $30 (Buy). The Motley Fool published a 'Is HIMS Stock a Buy After Latest Dip?' analysis on May 14 framing the post-print decline as a buying opportunity, citing the 9% subscriber growth to 2.6M, the raised full-year guide ($2.8-3.0B revenue, $275-350M Adjusted EBITDA), and the structural lift from the Novo Nordisk branded-Wegovy distribution deal landing in Q2 books. The split between bullish and cautious analyst takes captures the central tension: high-growth telehealth navigating a margin-dilutive product transition.
Wall Street's read of Hims & Hers' Q1 print delivered May 11 split between two camps. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed) on what analysts called a 'mixed' quarter, citing gross margin compression from 73% to 65% on the wind-down of compounded semaglutide. Canaccord raised its target to $32 from $30 (Buy) framing the quarter as a transition speed bump rather than a thesis break. The central question both calls land on: whether branded Novo Nordisk Wegovy/Ozempic distribution (live since March 26) can offset margin loss from the compounded business. Q1 books closed March 31, so meaningful Wegovy revenue contribution comes in Q2; subscriber count held at 2.6M (+9% YoY).
Hims & Hers reported Q1 2026 after market close May 11: revenue $608.1M (+4% YoY vs $586M prior year), missing the $616.9M consensus; subscribers up 9% to 2.6M; net loss of $92.1M ($0.41/share) vs $49.5M net income in Q1 2025. Gross margin compressed from 73% to 65% on the strategic pivot away from compounded semaglutide toward branded Novo Nordisk Wegovy/Ozempic supply (live since March 26). Q1 closed March 31 — meaningful Wegovy revenue contribution lands in Q2. Full-year 2026 guidance was raised: revenue to $2.8-3.0B and Adjusted EBITDA to $275-350M. The company is keeping limited compounded GLP-1 access alive alongside branded supply, threading the FDA April 30 503B bulks-list proposal.
Hims & Hers reports Q1 2026 after market close May 11, with consensus revenue at $616-619M and EPS at roughly 3-4 cents — a 90% YoY decline. The investor question is whether the legitimate Wegovy/Ozempic distribution channel from the Novo Nordisk partnership (signed April 2026) can offset the wind-down of the compounded semaglutide business. Novo's branded products were not on the platform until March 26, with Q1 books closing March 31 — meaningful Wegovy revenue contribution likely lands in Q2. Subscriber count above 2.5M and ~82% three-month retention remain the standing benchmarks. The April 30 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list raises the medium-term bar for any compounding-driven model.
Hims & Hers reports Q1 2026 results May 11 after market close. Company guidance: $600–625M revenue (2–7% YoY) and $35–55M adjusted EBITDA (~7% margin), with Q1 carrying a roughly $65M timing impact from the weight-loss shift to 503A fulfillment. Outlook (ex-Eucalyptus) is $2.7–2.9B revenue and $300–375M EBITDA. Hims also launched Testosterone Rx+ — a once-daily pill for low-libido idiopathic hypogonadism — as a non-GLP-1 specialty addition, signaling the wider longevity and peptide play the company has telegraphed for 2026. The California peptide-manufacturing facility acquired in February 2025 sits as a post-PCAC option for producing reclassified Category 1 peptides if the July meeting clears the path.
Hims & Hers shares climbed roughly 9% in early-week trading from $28.82 to $31 ahead of the company's May 11 Q1 2026 earnings, extending a five-session run that has lifted the stock about 49%. The catalysts: renewed FDA interest in peptides via the upcoming July PCAC meeting and the company's Novo Nordisk collaboration providing branded Wegovy and Ozempic access. Hims also flagged a 2026 longevity specialty launch covering peptides, coenzymes, and GLP/GIP treatments, and continues to invest in the California peptide-manufacturing facility acquired in February 2025 — which could pivot to producing reclassified Category 1 peptides if the July PCAC clears the path.
An investor-facing April 2026 deep dive analyzes Hims & Hers' transformation from compounded GLP-1 distributor to dual-supplier branded telehealth platform after the Novo Nordisk settlement (March 9, 2026), the Eli Lilly partnership expansion (April 23), and the FDA Category 2 peptide reclassification. The piece argues the California peptide manufacturing facility acquired in 2025 — originally for compounded GLP-1s — could pivot to producing reclassified peptides like BPC-157, TB-500, and KPV if July's PCAC clears the path.
Hims & Hers' announced $1.15 billion acquisition of Eucalyptus continues to be a major catalyst for the company alongside Friday's JPMorgan Overweight upgrade. Eucalyptus brings Australia and Japan exposure, with management targeting more than $1 billion in annual international revenue within three years. Combined with the recent Eli Lilly LillyDirect partnership (Foundayo, Zepbound, KwikPen) and the FDA peptide reclassification framework, Hims now has three strategic catalysts reshaping its 2026 trajectory.
Hims & Hers announced April 23 a strategic expansion of its U.S. weight loss platform, adding licensed-provider prescriptions for Eli Lilly's Zepbound vials, Zepbound KwikPen, and Foundayo. Prescriptions are fulfilled through LillyDirect pharmacy, completing a dual-supplier arrangement after last month's Novo Nordisk Wegovy collaboration. Shares jumped roughly 7% on the announcement as investors digested the company's pivot from compounded GLP-1s toward branded distribution.
JPMorgan initiated coverage of Hims & Hers on April 24 with an Overweight (Buy-equivalent) rating and a $35 price target, citing the Novo Nordisk and Eli Lilly partnerships, progress toward peptide legalization, and a likely revenue rebound in H2 2026. Shares jumped about 9.6% intraday Friday, representing roughly 25% upside from Thursday's close. The note specifically called out the Novo Nordisk deal as 'a turning point' that resolves the company's prior legal overhang from compounded GLP-1 production.
Eli Lilly shares closed down nearly 2% at $918.56 and Novo Nordisk fell ~4% on April 22 after CVS Health's decision to opt out of the Medicare obesity drug coverage pilot triggered CMS to scrap the BALANCE model. The combined market cap loss across the two GLP-1 leaders exceeded $25 billion. Hims & Hers dropped another 6% on continued Amazon One Medical competitive pressure.
Telehealth rival Hims & Hers Health shares slid 6% April 21-22 after Amazon's One Medical launched a comprehensive GLP-1 weight management program offering Wegovy and Foundayo starting at $25/month with insurance or $149/month cash-pay for oral options. The move positions Amazon against established telehealth obesity care providers (Hims, Ro, LifeMD, Noom) as the compounded-GLP-1 era winds down.